WFDC2 and endometrial cancer: Kaplan-Meier survival analysis showed that endometrial cancer patients with strongly positive expression of HE4 had significantly higher mortality than those without strongly positive expression of HE4 (P = 0.027, Figure 2(a)); with an increase in endometrial cancer stage, mortality also showed a rising trend, and the mortality of endometrial cancer at FIGO stages III-IV was significantly higher than that in patients at FIGO stages I-II; the difference was statistically significant (P = 0.010, Figure 2(b)).